None
SK
DataMeds AI, Inc. (MEDS) Stock: Corexa Pharmacy Eyes Stronger H2 2026 Growth
['Yasmin Werner']
Blockonomi
DataMEDS AI, Inc., MEDSCorexa Pharmacy Revenue Supports H2 Growth PlanCorexa Pharmacy generated more than $600,000 in July revenue, giving the business an annualized run rate above $7 million.
Corexa Pharmacy also completed its rebrand from Wellgistics Pharmacy, creating a clearer identity within DataMeds’ expanding healthcare operations.
These changes give the pharmacy a larger role across DataMeds’ pharmacy, telemedicine, technology, and consumer health services nationwide.
Corexa Pharmacy now carries Galectovid and Tollovid, along with other dietary supplements and nutraceutical products for broader consumer demand.
States should follow later in 2026 as DataMeds expands access and completes local operating requirements across targeted markets nationwide.